Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the Stifel 2025 Healthcare Conference in New York. Management is scheduled for a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025 at 11:20 a.m. ET. A live webcast will be available on the company investor relations website and the webcast will be archived for replay after the event.
Rapid Micro Biosystems (Nasdaq: RPID) parteciperà alla Stifel 2025 Healthcare Conference a New York. Il management è previsto per una sessione di domande e risposte di 30 minuti con l'analista ospite martedì 11 novembre 2025 alle 11:20 a.m. ET. Una trasmissione in diretta sarà disponibile sul sito delle Relazioni con gli Investitori dell'azienda e la webcast sarà archiviata per la riproduzione dopo l'evento.
Rapid Micro Biosystems (Nasdaq: RPID) participará en la Stifel 2025 Healthcare Conference en Nueva York. La dirección está programada para una sesión de preguntas y respuestas de 30 minutos con el analista anfitrión el martes 11 de noviembre de 2025 a las 11:20 a.m. ET. Una transmisión en vivo estará disponible en el sitio web de relaciones con inversionistas de la empresa y la transmisión se archivará para su reproducción después del evento.
Rapid Micro Biosystems (Nasdaq: RPID) 은 뉴욕에서 열리는 Stifel 2025 Healthcare Conference에 참석합니다. 경영진은 화요일 2025년 11월 11일 동부표준시 11:20에 주최 애널리스트와의 30분 질의응답 세션이 예정되어 있습니다. 생중계가 회사의 IR 웹사이트에서 제공되며 이벤트 후 재생을 위해 생중계가 보관됩니다.
Rapid Micro Biosystems (Nasdaq : RPID) participera à la Stifel 2025 Healthcare Conference à New York. La direction est prévue pour une session de questions-réponses de 30 minutes avec l’analyste hôte le mardi 11 novembre 2025 à 11 h 20, heure de l’Est. Une diffusion en direct sera disponible sur le site des relations investisseurs de l’entreprise et la diffusion sera archivée pour réécoute après l’événement.
Rapid Micro Biosystems (Nasdaq: RPID) wird an der Stifel 2025 Healthcare Conference in New York teilnehmen. Das Management ist für eine 30-minütige Frage-und-Antwort-Sitzung mit dem Gastgeber-Analysten am Dienstag, dem 11. November 2025 um 11:20 Uhr ET vorgesehen. Ein Live-Webcast wird auf der Website der Investor Relations des Unternehmens verfügbar sein und der Webcast wird nach der Veranstaltung zur Wiederholung archiviert.
Rapid Micro Biosystems (Nasdaq: RPID) ستشارك في مؤتمر Stifel للرعاية الصحية 2025 في نيويورك. من المقرر أن تعقد الإدارة جلسة أسئلة وأجوبة تستغرق 30 دقيقة مع المحلل المضيف يوم الثلاثاء 11 نوفمبر 2025 في الساعة 11:20 صباحاً بتوقيت شرق الولايات المتحدة. سيكون هناك بث مباشر متاح على موقع علاقات المستثمرين بالشركة وسيتم حفظ البث للمشاهدة مرة أخرى بعد الحدث.
- None.
- None.
LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2025 Healthcare Conference in New York, NY.
Company management is scheduled to participate in a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025, at 11:20 a.m. ET. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
 
             
             
             
             
             
             
             
         
         
         
        